AI assistant
Biotest AG — Share Issue/Capital Change 2005
Jun 30, 2005
66_rns_2005-06-30_f8159dbd-ec65-433b-a6dd-70a7809a2c06.html
Share Issue/Capital Change
Open in viewerOpens in your device viewer
News Details
Ad-hoc | 30 June 2005 20:40
Biotest AG: Biotest AG increases capital stock by EUR 2.92 million euro
Ad hoc announcement §15 WpHG Capitalization Biotest AG: Biotest AG increases capital stock by EUR 2.92 million euro Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Capitalization Biotest AG increases capital stock by EUR 2.92 million euro Dreieich, June 30, 2005. Biotest AG is increasing its share capital by 2.92 million euro to 23.40 million euro by issuing 1.14 million new ordinary shares. Biotest will thus receive fresh money for the accelerated development of monoclonal antibodies while simultaneously cutting financial debt. With the approval of the Supervisory Board the Executive Board of Biotest AG decided today the partial use of Authorised Capital excluding shareholders’ subscription rights. 570.000 new ordinary shares with an imputed interest of 1.46 million euro (6.24%) in the share capital were subscribed by a German financial investor against a cash contribution of 10.01 million euro. Additional 569.150 new ordinary shares were subscribed by Dr. Schleussner family, who previously held 60% and now holds 57.8% of ordinary shares from the conversion of a shareholder loan totaling 10 million euro. These measures have lifted the Biotest group’s equity ratio from 30.8% (as per March 31, 2005) to more than 36%. The issuing price was fixed in line with the statutory provisions with a discount of 5% compared to the average stock market price for the previous five trading days. The company’s new share capital totaling 23.40 million euro comprises 5.14 million ordinary shares and 4.0 million preferred shares, each with a proportionate interest of 2.56 euro. Investor Relations: Hubert Bötsch, Telephone: +49 (0) 6103 801-444, Telefax: +49 (0) 6103 801-880, E-mail: [email protected] Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, http://www.biotest.de WKN (German Securities Code), ISIN ordinary shares: 522720, DE0005227201 WKN (German Securities Code), ISIN preferred shares: 522723, DE0005227235 Listed: Amtlicher Handel in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg and Stuttgart Biotest AG Landsteinerstraße 5 63303 Dreieich Deutschland ISIN: DE0005227201; DE0005227235 WKN: 522720; 522723 Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg und Stuttgart End of ad hoc announcement (c)DGAP 30.06.2005 302040 Jun 05